Saniona

Saniona is a clinical-stage biopharmaceutical company headquartered in Denmark. Founded in 2011, the company is at the forefront of ion channel modulation for the treatment of epilepsy and other neurological disorders. Their epilepsy pipeline includes promising candidates such as SAN711 for absence seizures, SAN2219 for acute repetitive seizures, and SAN2355 for refractory focal onset seizures. In addition to epilepsy, Saniona is driving forward four clinical programs for collaboration. Notably, their partnerships with esteemed organizations like Boehringer Ingelheim GmbH and Productos Medix, S.A de S.V showcase their industry reputation. The company's most advanced candidate, Tesofensine, is making strides towards regulatory approval for obesity in Mexico through a partnership with Medix. Their commitment to rare eating disorders, inflammatory bowel disease, and major depressive disorder underscores their diverse and impactful approach to biotechnology. Saniona's recent $65.00M Post-IPO Equity investment on 10 August 2020, led by notable investors including New Leaf Venture Partners, Pontifax, RA Capital Management, Third Swedish National Pension Fund, Fourth Swedish National Pension Fund, and Andra AP-fonden, reflects the confidence and support garnered by the company. With their listing on Nasdaq Stockholm Main Market, Saniona is positioned for continued growth and innovation in the biotechnology sector. Learn more at www.saniona.com (OMX: SANION).